These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 22619886

  • 1. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease.
    Krairittichai U, Mahannopkul R, Bunnag S.
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S41-7. PubMed ID: 22619886
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
    Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK.
    Am J Kidney Dis; 2008 May; 51(5):724-31. PubMed ID: 18436082
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
    Susantitaphong P, Nakwan S, Peerapornratana S, Tiranathanagul K, Katavetin P, Srisawat N, Praditpornsilpa K, Eiam-Ong S.
    BMC Nephrol; 2017 Jan 14; 18(1):19. PubMed ID: 28088187
    [Abstract] [Full Text] [Related]

  • 5. Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria).
    Imai E, Haneda M, Chan JC, Yamasaki T, Kobayashi F, Ito S, Makino H.
    Nephrol Dial Transplant; 2013 Oct 14; 28(10):2526-34. PubMed ID: 24013685
    [Abstract] [Full Text] [Related]

  • 6. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
    Villar E, Lièvre M, Kessler M, Lemaître V, Alamartine E, Rodier M, François M, Zaoui P, Moranne O, Choukroun G, Guerraoui A, Jolivot A, Janin G, Branger B, Heng AE, Boudray C, Bissery A, Rabilloud M, Pouteil-Noble C.
    J Diabetes Complications; 2011 Oct 14; 25(4):237-43. PubMed ID: 21601481
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J.
    Am J Kidney Dis; 2007 Dec 14; 50(6):946-51. PubMed ID: 18037095
    [Abstract] [Full Text] [Related]

  • 8. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P, Eiam-Ong S, Suwanwalaikorn S.
    J Med Assoc Thai; 2006 Feb 14; 89(2):170-7. PubMed ID: 16579002
    [Abstract] [Full Text] [Related]

  • 9. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.
    Am J Kidney Dis; 2009 Oct 14; 54(4):647-52. PubMed ID: 19596163
    [Abstract] [Full Text] [Related]

  • 10. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar 14; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 11. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A, Amer W, Anwar E, Bashir K.
    Saudi J Kidney Dis Transpl; 2009 May 14; 20(3):429-35. PubMed ID: 19414946
    [Abstract] [Full Text] [Related]

  • 12. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 14; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 13. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ.
    Am J Kidney Dis; 2012 Jan 14; 59(1):75-83. PubMed ID: 22051245
    [Abstract] [Full Text] [Related]

  • 14. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.
    Clin Exp Hypertens; 2005 Jan 14; 27(2-3):129-38. PubMed ID: 15835375
    [Abstract] [Full Text] [Related]

  • 15. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr 14; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

  • 16. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
    Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ.
    Am J Kidney Dis; 2008 Sep 14; 52(3):464-74. PubMed ID: 18617301
    [Abstract] [Full Text] [Related]

  • 17. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May 14; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 18. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Matsumoto K.
    Pharmacotherapy; 2009 Sep 14; 29(9):1061-72. PubMed ID: 19698011
    [Abstract] [Full Text] [Related]

  • 19. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A, Hayashi K, Saruta T.
    Am J Hypertens; 2005 Jan 14; 18(1):44-9. PubMed ID: 15691616
    [Abstract] [Full Text] [Related]

  • 20. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G.
    Kidney Int Suppl; 1997 Dec 14; 63():S54-7. PubMed ID: 9407422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.